Why Is CV Sciences Stock Up Today?
CV Sciences (OTCQB: CVSI) shares were trading 10.69% higher at $0.044 per share at the time of writing Monday morning on company's third-quarter financial results.
LFTD Partners Q3 Revenue Grows 27% YoY To $11.2M
LFTD Partners Inc. (OTCQB: LIFD) Q3 2022 revenue was $11.2 million, a 27% increase compared to $8.8 million in Q3 2021.
Q3 2022 Financial Highlights
Net income of $423,486
Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), released financial results for the third quarter ended September 30, 2022.
Q3 2022 Financial Highlights
MediPharm Touts Strong Q3 Revenue Growth, Continues To Expand Internationally
MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) announced on Monday its financial results for the three months ended Sept. 30, 2022.
Where To Buy Legal Weed These Days: Jushi Expands In PA, NJ Gets Another MMJ Shop & More
Jushi Expands Retail Footprint In Pennsylvania
Jushi Holdings Inc. (CSE: JUSH) (OTCQX: JUSHF) has opened its relocated Beyond Hello Westside dispensary in Pennsylvania through its subsidiary, Pennsylvania Dispensary Solutions.
IM Cannabis Revenue Grows 78% YoY, What About Debt?
IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC) Q3 2022 revenues were CA$14.2 million ($10.7 million), compared to CA$8.0 million on Q3 2021, an increase of 78%, representing a 12% sequential organic growth.
MindMed’s Q3 2022 Financials & Business, Setting The Stage For Phase 3 Trials
Clinical-stage biotech company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022.
Filament Health Shares Q3 2022 Results, On Road To Becoming Industry’s Natural Psilocybin Supplier
Clinical-stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) reported its third quarter financial results and operational highlights for the period ended September 30, 2022.
Ayr Wellness: Analyst Reduces Price Target And Stays Neutral After Q3 Results
On Thursday, Ayr Wellness Inc. (CSE: AYR.A) (OTCQX: AYRWF) reported its financial results for the third quarter that ended September 30, 2022, with revenue of $119.6 million
Novel Psychedelic Compound For The Treatment Of Fibromyalgia Begins Dosing In Safety Trial
Developmental-stage psychedelics biotech company Silo Pharma Inc. (NASDAQ: SILO) has begu